Handa Pharmaceuticals, Inc.

TPEX:6620 Stock Report

Market Cap: NT$8.2b

Handa Pharmaceuticals Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Handa Pharmaceuticals.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth58.7%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated22 Aug 2024

Recent future growth updates

No updates

Recent updates

Handa Pharmaceuticals'(GTSM:6620) Share Price Is Down 26% Over The Past Three Years.

Feb 24
Handa Pharmaceuticals'(GTSM:6620) Share Price Is Down 26% Over The Past Three Years.

We Think Handa Pharmaceuticals (GTSM:6620) Can Afford To Drive Business Growth

Dec 29
We Think Handa Pharmaceuticals (GTSM:6620) Can Afford To Drive Business Growth

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Handa Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TPEX:6620 - Analysts future estimates and past financials data (TWD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20242,5502,0801,9101,9141
6/30/2024973452745747N/A
3/31/2024992597917917N/A
12/31/20231,106727667668N/A
9/30/2023956707394394N/A
6/30/20237235407980N/A
3/31/2023508250-124-123N/A
12/31/2022198-40-212-212N/A
9/30/202256-173-162-160N/A
6/30/202256-217-135-134N/A
3/31/202243-233-161-157N/A
12/31/202129-248-186-179N/A
9/30/202129-250-242-233N/A
6/30/202129-253-298-286N/A
3/31/202129-268-307-297N/A
12/31/202029-282-316-308N/A
9/30/202034-273-276-271N/A
6/30/202038-263-237-234N/A
3/31/202061-220-236-235N/A
12/31/201984-178-236-235N/A
9/30/201993-160-243-236N/A
6/30/2019103-141-250-237N/A
3/31/201998-154-220-207N/A
12/31/201894-167-191-177N/A
9/30/201881-167-156-148N/A
6/30/201869-167-122-118N/A
3/31/201830363N/A173N/A
12/31/2017538293N/A464N/A
9/30/2017620368N/A465N/A
6/30/2017702442N/A467N/A
3/31/2017457235N/A167N/A
12/31/201621129N/A-133N/A
9/30/2016119-43N/A-138N/A
6/30/201628-115N/A-143N/A
3/31/201614-121N/A-126N/A
12/31/2015N/A-128N/A-109N/A
12/31/20143-17N/A-11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 6620's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if 6620's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 6620's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 6620's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 6620's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 6620's Return on Equity is forecast to be high in 3 years time


Discover growth companies